<?xml version="1.0" encoding="UTF-8"?>
<p id="p0075">The live-attenuated virus vaccine, composed of recombinant SARS-CoV lacking the E gene (rSARS-Cov-E), produces significant neutralizing antibodies and virus-specific T cell responses
 <xref rid="bib55" ref-type="bibr">
  <sup>55</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib56" ref-type="bibr">
  <sup>56</sup>
 </xref>. More recently, a live attenuated SARS-CoV was generated through mutation of transcription regulatory networks (TRNs), where the attenuated virus effectively limits virulence reversal and protects mice against challenge
 <xref rid="bib57" ref-type="bibr">
  <sup>57</sup>
 </xref>. Another study reported that rMERS-CoV-Î”E, a mutant of the MERS-CoV prepared using a new DNA cloning vector system, only replicates in a small number of cells, but can produce enough antigen to stimulate protective immunity in the host
 <xref rid="bib58" ref-type="bibr">
  <sup>58</sup>
 </xref>. Although vaccine candidates based on the live-attenuated coronaviruses have the potential to induce a highly effective immune response and protection, it may present biosafety problems associated with virulence recovery
 <xref rid="bib55" ref-type="bibr">
  <sup>55</sup>
 </xref>.
</p>
